<DOC>
	<DOCNO>NCT01289210</DOCNO>
	<brief_summary>This study determine safety effectiveness VTX-2337 ( investigational drug stimulates immune system ) combination radiation therapy treat patient low-grade B-cell lymphoma . Patients receive 2 low dos radiotherapy , 9 intratumoral injection VTX-2337 course 3 month .</brief_summary>
	<brief_title>VTX-2337 Combination With Radiotherapy Patients Low-Grade B-cell Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Major low grade B cell lymphoma 1 site disease appropriate intratumoral injection measurable disease injection site Performance Status 1 good Adequate bone marrow , renal hepatic function No active autoimmune disease systemic immunosuppressive drug Life expectancy &gt; 4 month Known HIV Known brain metastasis Malignancy within last 5 yr ( basal cell noninvasive squamous cell carcinoma OK ) Anticoagulation therapy 325mg QD ASA Significant cardiovascular disease Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>B cell</keyword>
	<keyword>lymphoma</keyword>
</DOC>